Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antares Pharma (ATRS)

Antares Pharma (ATRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 469,972
  • Shares Outstanding, K 162,620
  • Annual Sales, $ 63,550 K
  • Annual Income, $ -6,520 K
  • 60-Month Beta 0.91
  • Price/Sales 7.65
  • Price/Cash Flow N/A
  • Price/Book 11.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.04
  • Number of Estimates 5
  • High Estimate -0.03
  • Low Estimate -0.04
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +12.36%
on 06/03/19
3.12 -2.25%
on 06/18/19
+0.11 (+3.92%)
since 05/24/19
3-Month
2.60 +17.11%
on 04/18/19
3.14 -2.89%
on 03/25/19
-0.08 (-2.41%)
since 03/22/19
52-Week
2.45 +24.03%
on 06/27/18
3.96 -23.11%
on 03/04/19
+0.35 (+13.19%)
since 06/22/18

Most Recent Stories

More News
Topical Drug Delivery Market 2019: Detail Analysis Focusing on Key Players like Galderma S.A., Valeant Pharmaceuticals International, Crescita Therapeutics, 3M, Bayer AG, Novartis AG, Janssen Global Services, West Pharmaceutical Services, Others

Global Topical Drug Delivery Market research report is generated with the best and advanced tools of collecting, recording, estimating and analysing market data. The report includes a range of inhibitors...

VRX.TO : 30.80 (-3.33%)
CRRTF : 0.5399 (-0.02%)
HTSUF : 41.1000 (unch)
AGN : 129.45 (-1.04%)
ATRS : 3.06 (+5.88%)
NVS : 92.73 (+0.26%)
ABBV : 78.38 (-0.51%)
ACRS : 4.48 (-1.32%)
PFE : 43.78 (+0.25%)
Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday...

ATRS : 3.06 (+5.88%)
Antares Pharma: 1Q Earnings Snapshot

EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Thursday reported a loss of $5.5 million in its first quarter.

ATRS : 3.06 (+5.88%)
Antares Pharma Reports First Quarter 2019 Operating and Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) ("the Company") today reported operating and financial results for the first quarter ended March 31, 2019. The Company reported revenue of $23.3 million and a net loss...

ATRS : 3.06 (+5.88%)
Antares Pharma to Report First Quarter 2019 Financial and Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019. Management...

ATRS : 3.06 (+5.88%)
Transdermal/Transmucosal Drug Delivery System Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2024

Market Study Report newly added the Global Transdermal/Transmucosal Drug Delivery System Market Report that gives meticulous investigation of current scenario of the market size, share, demand, growth,...

DRRX : 0.64 (+4.92%)
ATRS : 3.06 (+5.88%)
CORI : 12.68 (+0.24%)
ZSAN : 3.17 (+1.60%)
New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Progress Software Corporation...

EYE : 31.19 (-2.38%)
KELYB : 23.40 (+11.59%)
ATRS : 3.06 (+5.88%)
NMIH : 29.03 (-2.09%)
PRGS : 40.51 (-0.20%)
WAT : 212.66 (-0.07%)
KELYA : 24.86 (+0.65%)
Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

Antares Pharma, Inc. (NASDAQ: ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate ("MTX") for the treatment of ectopic pregnancy that meets predefined...

ATRS : 3.06 (+5.88%)
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.

CELG : 93.56 (-5.41%)
BDSI : 4.36 (-0.91%)
ATRS : 3.06 (+5.88%)
AMAG : 8.51 (-5.13%)
Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39 Annual Healthcare Conference on Wednesday March...

ATRS : 3.06 (+5.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ATRS with:

Business Summary

Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes...

See More

Key Turning Points

2nd Resistance Point 3.06
1st Resistance Point 2.97
Last Price 3.05
1st Support Level 2.83
2nd Support Level 2.78

See More

52-Week High 3.96
Fibonacci 61.8% 3.39
Fibonacci 50% 3.21
Last Price 3.05
Fibonacci 38.2% 3.03
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar